Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 85 EUR
  • 100 mg - 255 EUR
  • 250 mg - 510 EUR

Tandutinib

Tandutinib is a potent inhibitor of the FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit kinases (IC50 approximately 200 nM), but has little effect on other tyrosine or serine/threonine kinases. Tandutinib inhibited FLT3 phosphorylation, downstream signaling and malignant growth in vitro and in animal models. The compound displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin. It is currently undergoing Phase II clinical trials in patients with AML or renal cell carcinoma.

catalogue number: T107
synonyms: MLN518, CT53518
CAS: 387867-13-2
MW: 562.72 g/mol

References
Cancer Cell. 2002 Jun;1(5):421-32. PMID: 12124172
J Med Chem. 2002 Aug 15;45(17):3772-93. PMID: 12166950
IDrugs. 2008 Jan;11(1):46-56. PMID: 18175263